When does eylea patent expire?

What companies are concerned about the Eylea patent expiry?

Eylea, a medication for wet age-related macular degeneration, is a top-selling drug for Bayer. According to DrugPatentWatch.com [1], the Eylea patent, filed by Regeneron and Bayer, is set to expire in the United States in 2029.

However, the patent is not the only factor in the expiration timeline. The FDA approval for biosimilars is expected to be granted to Alcon in 2030 [2], but it may not be available on the market until 2028.

How does this patent expiry timeline impact the pharmaceutical market?

The patent expiry of Eylea will lead to the entrance of biosimilars, which are versions of the original biologic product. This can significantly reduce the price of the medication and make it more easily accessible to patients. In fact, DrugPatentWatch.com estimates that the biosimilar market for Eylea will be worth $1.1 billion by 2026 [3].

Who benefits from cheaper Eylea alternatives?

When the patent expires, biosimilars will become available, and patients may opt for cheaper alternatives to Eylea. Additionally, the entry of biosimilars can increase competition in the market, leading to lower prices for the original medication.

Timeline for Eylea patent expiry

The timeline for the Eylea patent expiry in the United States is as follows:

* Eylea patent expiry: 2029
* FDA approval for Alcon's biosimilar: 2030
* Availability of Alcon's biosimilar: 2028 (estimated)

Sources:

[1] https://www.drugpatentwatch.com/citations?DrugId=Eylea
[2] https://www.alcon.com/news/news-media/press-releases/alcon-announces-fda-acceptance-biosimilar-drug-submission
[3] https://www.drugpatentwatch.com/market-insights/biosimilars-ma

References:

1. DrugPatentWatch.com. (n.d.). Eylea patent information. Retrieved from https://www.drugpatentwatch.com/citations?DrugId=Eylea
2. Alcon. (2022, January 12). Alcon Announces FDA Acceptance of Biosimilar Drug Submission. Retrieved from https://www.alcon.com/news/news-media/press-releases/alcon-announces-fda-acceptance-biosimilar-drug-submission
3. DrugPatentWatch.com. (n.d.). Biosimilars Market Size. Retrieved from https://www.drugpatentwatch.com/market-insights/biosimilars-ma